CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 692 enrolled
Drug / intervention
Recombinant tissue plasminogen activator (rt-PA)drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00790335
NCT00790335Phase 3Completed
CompareCT.gov

Acute Venous Thrombosis: Thrombus Removal With Adjunctive Catheter-Directed Thrombolysis--The ATTRACT Trial

Washington University School of Medicine·interventional·Posted Nov 13, 2008·Updated Mar 29, 2018

In Brief

A Phase 3 clinical trial evaluating Recombinant tissue plasminogen activator (rt-PA) for Deep Vein Thrombosis and 4 related conditions. Completed, enrolled 692 participants across 56 sites.

Detailed Summary

The purpose of this study is to determine if the use of adjunctive Pharmacomechanical Catheter Directed Thrombolysis, which includes the intrathrombus administration of rt-PA--Activase (Alteplase),can prevent the post-thrombotic syndrome(PTS)in patients with symptomatic proximal deep vein thrombosis(DVT)as compared with optimal standard DVT therapy alone.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDeep Vein Thrombosis, Venous Thrombosis, Postphlebitic Syndrome, Venous Thromboembolism, Post Thrombotic Syndrome
CountriesUnited States
CollaboratorsMcMaster University, Ontario Clinical Oncology Group (OCOG), National Heart, Lung, and Blood Institute (NHLBI), BSN Medical Inc, Genentech, Inc., Medtronic - MITG, Boston Scientific Corporation, Mid America Heart Institute, Society of Interventional Radiology Foundation, Massachusetts General Hospital

Timeline

Phase 3CompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
First PostedNov 13, 2008
Enrollment StartNov 1, 2009
Primary CompletionJan 1, 2017
TodayJul 2, 2026
Enrollment to primary: 7.2 yearsPosted 17.6 years ago

Interventions

Recombinant tissue plasminogen activator (rt-PA)drug

Pharmacomechanical catheter-directed thrombolysis, consisting of intrathrombus administration of rt-PA using a catheter/device.